Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
DAWN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.88 - $18.07
Previous CloseN/A
Volume175.11K
Average Volume (3M)1.29M
Market Cap
$839.22M
Enterprise Value$752.02M
Total Cash (Recent Filing)$49.27M
Total Debt (Recent Filing)$717.00K
Price to Earnings (P/E)―
Beta1.44
Next Earnings
May 07, 2025EPS Estimate
-0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding101,354,515
10 Day Avg. Volume1,187,657
30 Day Avg. Volume1,285,540
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.36
Price to Cash Flow (P/CF)-7.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.97
Enterprise Value/Ebitda-3.48
Forecast
1Y Price Target
$34.13Price Target Upside320.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Day One Biopharmaceuticals News
---
Bulls Say, Bears Say
Bulls Say
Drug LaunchOJEMDA's launch is viewed as strong, with a +44% growth rate, supported by higher prescription volumes and improved revenue.
Financial PerformanceThe classification of OJEMDA as a pediatric-only therapy by CMS resulted in a reduction in the Medicaid and 340B rebate percentage, positively impacting revenue.
Physician And Patient AdoptionGrowing prescriber confidence is reflected in the fact that all high-priority treatment centers have now prescribed OJEMDA to at least one patient.
Bears Say
Clinical TrialsNew adverse events could lead to disruption in trial progress.
Market AdoptionIncreased treatment discontinuation rates could lead to limited market adoption post approval.
---
Ownership Overview
17.68% Insiders
20.52% Mutual Funds
0.19% Other Institutional Investors
50.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $7.88 and its highest was $18.07 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Day One Biopharmaceuticals’s market cap is $839.22M.
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is May 07, 2025 which is in 40 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on Feb 25, 2025. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.362 by -$0.268.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -0.42.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 101,354,515 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.362. Following the earnings report the stock price went down -16.497%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Currently, no hedge funds are holding shares in DAWN
---
Day One Biopharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.13 (320.32% Upside)
$34.13 (320.32% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 7.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.87%
12-Months-Change
Fundamentals
Return on Equity
-22.49%
Trailing 12-Months
Asset Growth
54.98%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
---
DAWN Company Deck
---
DAWN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements like the FDA approval and commercial success of OJEMDA, coupled with strong financials and strategic partnerships. However, challenges include some product discontinuations and slower adoption in certain accounts. Overall, the positives outweigh the negatives, indicating strong company momentum.Read More>---
DAWN Stock 12 Month Forecast
Average Price Target
$34.13
▲(320.32% Upside)
Technical Analysis
Best Analysts Covering DAWN
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
+0.04%
reiterated a buy rating 8 months ago
Copying Robert Driscoll's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +0.04% per trade.
---